Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

6.570 -0.010 (-0.15%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Crude Oil Moves Higher; Apple Shares Slide After Q4 Results ↗
 
Via Benzinga
News headline image
Analyst Expectations For Myriad Genetics's Future ↗
 
Via Benzinga
News headline image
Myriad Genetics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) ↗
 
Via Benzinga
News headline image
Key Takeaways From Myriad Genetics Analyst Ratings ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results ↗
 
Via Benzinga
News headline image
Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
Management will also participate in two upcoming investor healthcare conferences 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference
MyRisk®, FirstGene®, Prequel®, and Foresight® studies among 10 datasets to be shared by Myriad 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
G-III Apparel Posts Upbeat Results, Joins NIO, Yext, Shoe Carnival And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Myriad Genetics to Host Investor Event on October 9, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Thermo Fisher Scientific Stock Sees RS Rating Jump To 81 ↗
Thermo Fisher Scientific stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 77 to 81. 
Via Investor's Business Daily
News headline image
MYGN Stock Earnings: Myriad Genetics Beats EPS, Beats Revenue for Q2 2024 ↗
MYGN stock results show that Myriad Genetics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Avantor Stock Earns 84 RS Rating ↗
Avantor stock had its Relative Strength (RS) Rating upgraded from 78 to 84 Tuesday amid positive Q2 earnings results. 
Via Investor's Business Daily
News headline image
Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
New Nationwide Survey Findings Show That More Than Half of Women Do Not Know That Breast Density Can Reveal Increased Risk of Breast Cancer 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
The 3 Best Gene Editing Stocks to Buy in July 2024 ↗
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. 
Via InvestorPlace
News headline image
Myriad Genetics Earns 2024 Great Place To Work® Certification™
From Myriad Genetics, Inc.
Via GlobeNewswire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.